Cover
Cover | May 18, 2023 |
Cover [Abstract] | |
Document Type | 8-K/A |
Amendment Flag | true |
Amendment Description | As previously disclosed in the Current Report on Form 8-K filed by Iovance Biotherapeutics, Inc. (the "Company") with the Securities and Exchange Commission (the "SEC") on January 23, 2023, the Company and its newly formed, wholly owned subsidiary, Iovance Biotherapeutics UK Ltd ("Purchaser") entered into an Option Agreement (the "Option Agreement") with Clinigen Holdings Limited, Clinigen Healthcare Limited, and Clinigen, Inc. (collectively, "Clinigen"), pursuant to which the Purchaser would acquire the worldwide rights in Proleukin (aldesleukin), as well as the manufacturing, supply, commercialization and the generation of income from such rights and associated operations from Clinigen (the "Acquisition"). On May 18, 2023, the Company filed a Current Report on Form 8-K (the "Closing 8-K") with the SEC to report that the closing of the Acquisition occurred on May 18, 2023, following the satisfaction or waiver of the closing conditions under the Option Agreement. This Current Report on Form 8-K/A (this "Amendment No. 1") amends the Closing 8-K to provide the financial statements and pro forma financial information required by Items 9.01(a) and 9.01(b) of Form 8-K that were previously omitted from the Closing 8-K in reliance on Items 9.01(a)(4) and 9.01(b)(2) of Form 8-K. This Amendment No. 1 does not amend any other item of the Closing 8-K and all other information previously reported in or filed with the Closing 8-K is hereby incorporated by reference to this Amendment No. 1. |
Document Period End Date | May 18, 2023 |
Entity File Number | 001-36860 |
Entity Registrant Name | IOVANCE BIOTHERAPEUTICS, INC. |
Entity Central Index Key | 0001425205 |
Entity Tax Identification Number | 75-3254381 |
Entity Incorporation, State or Country Code | DE |
Entity Address, Address Line One | 825 Industrial Road |
Entity Address, Address Line Two | 4th Floor |
Entity Address, City or Town | San Carlos |
Entity Address, State or Province | CA |
Entity Address, Postal Zip Code | 94070 |
City Area Code | 650 |
Local Phone Number | 260-7120 |
Written Communications | false |
Soliciting Material | false |
Pre-commencement Tender Offer | false |
Pre-commencement Issuer Tender Offer | false |
Title of 12(b) Security | Common stock, par value $0.000041666 per share |
Trading Symbol | IOVA |
Security Exchange Name | NASDAQ |
Entity Emerging Growth Company | false |